Rebecca Lee
Title
Cited by
Cited by
Year
Application of sequencing, liquid biopsies, and patient-derived xenografts for personalized medicine in melanoma
MR Girotti, G Gremel, R Lee, E Galvani, D Rothwell, A Viros, AK Mandal, ...
Cancer discovery 6 (3), 286-299, 2016
1542016
The mutational burden of acral melanoma revealed by whole‐genome sequencing and comparative analysis
SJ Furney, S Turajlic, G Stamp, JM Thomas, A Hayes, D Strauss, ...
Pigment cell & melanoma research 27 (5), 835-838, 2014
722014
Facilitating reproductive choices: the impact of health services on the experiences of young women with breast cancer
RJ Lee, A Wakefield, S Foy, SJ Howell, AM Wardley, AC Armstrong
Psycho‐Oncology 20 (10), 1044-1052, 2011
672011
Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma
RJ Lee, G Gremel, A Marshall, KA Myers, N Fisher, JA Dunn, N Dhomen, ...
Annals of Oncology 29 (2), 490-496, 2018
642018
Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer
M Howell, R Lee, S Bowyer, A Fusi, P Lorigan
Lung Cancer 88 (2), 117-123, 2015
572015
Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients
S Valpione, G Gremel, P Mundra, P Middlehurst, E Galvani, MR Girotti, ...
European Journal of Cancer 88, 1-9, 2018
552018
Cancelled operations: a 7-day cohort study of planned adult inpatient surgery in 245 UK National Health Service hospitals
DJN Wong, SK Harris, SR Moonesinghe, SR Moonesinghe, DJN Wong, ...
British journal of anaesthesia 121 (4), 730-738, 2018
372018
Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA
G Gremel, RJ Lee, MR Girotti, AK Mandal, S Valpione, G Garner, M Ayub, ...
Annals of Oncology 27 (10), 1959-1965, 2016
352016
Influence of the MTHFR genotype on the rate of malformations following exposure to antiepileptic drugs in utero
U Kini, R Lee, A Jones, S Smith, S Ramsden, A Fryer, J Clayton-Smith, ...
European journal of medical genetics 50 (6), 411-420, 2007
312007
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study
LYW Lee, JB Cazier, T Starkey, SEW Briggs, R Arnold, V Bisht, S Booth, ...
The Lancet Oncology 21 (10), 1309-1316, 2020
302020
Application of sequencing, liquid biopsies, and patient-derived xenografts for personalized medicine in melanoma. Cancer Discov. 2016; 6: 286–299. doi: 10.1158/2159-8290
MR Girotti, G Gremel, R Lee, E Galvani, D Rothwell, A Viros, AK Mandal, ...
CD-15-1336.[Abstract][CrossRef][Google Scholar], 0
26
Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA
L Tan, S Sandhu, RJ Lee, J Li, J Callahan, S Ftouni, N Dhomen, ...
Annals of Oncology 30 (5), 804-814, 2019
252019
Myosin II reactivation and cytoskeletal remodeling as a hallmark and a vulnerability in melanoma therapy resistance
JL Orgaz, E Crosas-Molist, A Sadok, A Perdrix-Rosell, O Maiques, ...
Cancer cell 37 (1), 85-103. e9, 2020
102020
Survival of patients with early invasive melanoma down-staged under the new eighth edition of the American Joint Committee on Cancer staging system
LA von Schuckmann, MCB Hughes, R Lee, P Lorigan, K Khosrotehrani, ...
Journal of the American Academy of Dermatology 80 (1), 272-274, 2019
72019
Letrozole: advancing hormone therapy in breast cancer
RJ Lee, AC Armstrong, AM Wardley
Women’s Health 8 (6), 611-618, 2012
72012
Emerging targeted combinations in the management of breast cancer
RJ Lee, AC Armstrong, AM Wardley
Breast Cancer: Targets and Therapy 5, 61, 2013
62013
Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital
M Gleeson, C Peckitt, D Cunningham, A Gibb, EA Hawkes, M Back, ...
Leukemia & Lymphoma 59 (7), 1586-1595, 2018
42018
Cancer: Tumours addicted to drugs are vulnerable
RJ Lee, R Marais
Nature 550 (7675), 192-193, 2017
32017
Therapeutic efficacy of the paradox-breaking panRAF and SRC drug CCT3833/BAL3833 in KRAS-driven cancer models
G Saturno, F Lopes, MR Girotti, I Niculescu-Duvaz, D Niculescu-Duvaz, ...
European Journal of Cancer 61, S199, 2016
32016
Abstract LB-212: Therapeutic efficacy of the paradox-breaking panRAF and SRC drug CCT3833/BAL3833 in KRAS-driven cancer models
G Saturno, F Lopes, MR Girotti, I Niculescu-Duvaz, D Niculescu-Duvaz, ...
Cancer Research 76 (14 Supplement), LB-212-LB-212, 2016
22016
The system can't perform the operation now. Try again later.
Articles 1–20